Small molecule kinase inhibitors are a form of enzyme inhibitors and
are mostly used for the treatment of cancer. Protein kinase aids in
the development and progression of tumors and small molecule kinase
inhibitors help in obstructing unregulated cell cycle. The growing
incidence of cancer cases around the globe is one of the major
factors that propel the small molecule kinase inhibitors market. This
has driven pharma companies and regulatory bodies to further speed up
the process of clinical trials and drug approvals.
The research report analyzing the small molecule kinase inhibitors
market studies the industrial landscape and presents a qualitative
and quantitative portrait of the expected performance of the market
from 2013 to 2019.
Report Overview @
https://www.transparencymarketresearch.com/small-molecule-kinase-inhibitors-market.html
The data is derived from primary and secondary research, ensuring
absolutely unbiased and authentic evaluation of the small molecule
kinase inhibitors market. With the help of Porter’s five forces
analysis, the report studies the role of buyers, suppliers,
substitutes, new entrants, and competitors in the global market.
Growth factors, challenges, and opportunities are identified and
discussed at length and added emphasis is laid on government
regulations that govern that pharmaceutical industry
The small molecule kinase inhibitors market is projected to witness
robust growth in the coming years with rising popularity of the next
generation of kinase inhibitor drugs, multi-targeted kinase
inhibitors, and combination drug therapies. The use of kinase
inhibitors for the treatment of various oncology and non-oncology
diseases has grown, and while cancer end-use application areas are
much stronger, non-cancer therapies are bound to gain interest.
Download Report Brochure @
https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=2110
Key kinase inhibitor drugs that have made a significant contribution
to the global market include Sorafenib, Gefitinib, Iressa,
Temsirolimus, Imatinib, Dasatinib, Rapamycin, Nilotinib, Everolimus,
Sunitinib, Erlotinib, and Lapatinib. These commercially-available
drugs are designed to target and treat specific diseases. There are
numerous small molecule kinase inhibitor drugs in the pipeline, a
factor that is anticipated to boost the global market. These pipeline
drugs include Pazopanib, Cediranib, CP-690550, Bosutinib, Vandetanib,
Alvocidib, Motesanib, and Ridaforolimus.
Despite the availability of a number of kinase inhibitors, the
anticipated rise in cancer cases all over the world poses high
potential for the growth of the small molecule kinase inhibitors
market. However, strict regulatory riders, lengthy approval
procedures, and mounting costs of next-generation cancer drugs are
matters of concern that hamper the expansion of the small molecule
kinase inhibitors market.
Pre-Book Full Report @
https://www.transparencymarketresearch.com/checkout.php?rep_id=2110<ype=S
Prominent names in the small molecule kinase inhibitors market
include Bristol-Myers Squibb, Amgen, KAI Pharmaceuticals, Onyx
Pharmaceuticals, Wyeth, OSI Pharmaceuticals, Glaxo SmithKline, Merck
& Co, Pfizer, Bayer Schering Pharma, Roche, Sanofi-Aventis,
AstraZeneca, Novartis, Genentech, and Celgene Corporation. The
research study discusses these companies with respect to company
overview, financial standing, product portfolio, recent developments
in the small molecule kinase inhibitors market, mergers and
acquisitions, business strategies, and SWOT analysis.
About Us
Transparency Market Research (TMR) is a market intelligence company,
providing global business information reports and services. Our
exclusive blend of quantitative forecasting and trends analysis
provides forward-looking insight for thousands of decision makers.
TMR’s experienced team of analysts, researchers, and consultants,
use proprietary data sources and various tools and techniques to
gather, and analyze information. Our business offerings represent the
latest and the most reliable information indispensable for businesses
to sustain a competitive edge.
Each TMR syndicated research report covers a different sector - such
as pharmaceuticals, chemicals, energy, food & beverages,
semiconductors, med-devices, consumer goods and technology. These
reports provide in-depth analysis and deep segmentation to possible
micro levels. With wider scope and stratified research methodology,
TMR’s syndicated reports strive to provide clients to serve their
overall research requirement.
US Office Contact
90 State Street, Suite 700
Albany, NY 12207
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453
Email:
sales@transparencymarketresearch.com
Website:
https://www.transparencymarketresearch.com
No comments:
Post a Comment